BiotechTube

fidaxomicin + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile-Associated Diarrhea (CDAD)

Conditions

Clostridium Difficile-Associated Diarrhea (CDAD)

Trial Timeline

Oct 10, 2012 → Apr 16, 2015

NCT ID
NCT01691248

About fidaxomicin + Placebo

fidaxomicin + Placebo is a phase 3 stage product being developed by Merck for Clostridium Difficile-Associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT01691248. Target conditions include Clostridium Difficile-Associated Diarrhea (CDAD).

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile-Associated Diarrhea (CDAD) were approved

Approved (9) Terminated (5) Active (11)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
✅Vancomycin + FidaxomicinMerckApproved
✅bezlotoxumab + Vancomycin OralMerckApproved
✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved
✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01691248Phase 3Completed

Competing Products

20 competing products in Clostridium Difficile-Associated Diarrhea (CDAD)

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
FidaxomicinMerckPre-clinical
18
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40